Inaugural EUnetCCC Educational Seminar Programme Overview

Time Session
8:45 – 9:30 Registration and Welcome Coffee
9:30 - 9:40 Opening Remarks
Gro Live Fagereng, Oslo University Hospital Comprehensive Cancer Center, Norway
Alejandro Piris Giménez, Vall d’Hebron Institute of Oncology, Spain
9:40 – 11:00 Session 1: Molecular Tumour Boards as part of Standard-of-Care
9:40 – 10:20 Molecular Tumour Board – an Introduction
Arnaud Bayle, Gustave Roussy, France
10:20 – 11:00 Patient Eligibility and Ethical Considerations
Luigi de Petris, Karolinska Comprehensive Cancer Center and Karolinska Institutet, Sweden
11:00 - 11:30   Coffee Break
11:30 – 13:00 Session 2: Molecular Profiling and Preanalytical Considerations
11:30 – 12:00 Introduction to Molecular Cancer Biomarkers and Detection Methods
Albrecht Stenzinger, University Hospital Heidelberg, Germany
12:00 – 12:30 Best Practices for Sample Preparation in Molecular Profiling
Erika Tóth, National Institute of Oncology, Hungary
12:30 – 13:00 Liquid Biopsy: From Discovery to Clinical Implementation
Klaus Pantel, Universitätsklinikum Hamburg Eppendorf, Germany
13:00 - 14:00   Lunch Break
14:00 – 14:15   Quiz on Sessions 1 and 2
14:15 – 15:45 Session 3: Next Generation Technologies in Precision Oncology
14:15 – 14:35 Standardised Bioinformatics Pipelines for Variant Calling, Annotation, and Prioritisation
Lara Nonell, Vall d’Hebron Institute of Oncology, Spain
14:35 – 15:00 Data Quality Control in Clinical testing
Ana Vivancos, Vall d’Hebron Institute of Oncology, Spain
15:00 – 15:45 Multi-Layered Tumor Profiling for Precision Oncology
Stefan Fröhling, National Center for Tumor Diseases, Germany
15:45 – 16:00 Quiz on Session 3
16:00 - 16:30   Coffee Break
16:30 - 17:30 Featured Session 1: Demonstration of MTB workflow through Simulated MTB session
Loic Veringue, Centre Léon Bérard, France
Paul Roepman, Hartwig Medical Foundation, Netherlands
Åsmund Flobak, Norwegian University of Science and Technology, St Olav's University
Hospital and SINTEF, Norway
Rest of the panel to be confirmed
19:00 - 21:00   Conference Dinner
Time Session
8:30 – 9:00 Welcome Coffee
9:00 – 11:30 Session 4: Variant Annotation and Clinical Actionability
9:00 – 9:45 CGI-Clinics: Data-driven Cancer Genome Interpretation for Clinical Decision Making
Núria Lopez-Bigas, IRB Barcelona, Spain
9:45 – 10:15 Clinical Decision Support Systems: Implementation for Clinical Trial Inclusion and Routine Diagnostics
Anders Edsjö, Skåne University Hospital and Lund University, Sweden
10:15 – 10:45 Mind the Gap: Bridging Innovation and Clinical Access in Precision Oncology
Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Leiden University Medical Centre and CZ Health Insurance, Netherlands
10:45 - 11:05   Coffee Break
11:05 – 11:45 Featured Session 2: Integrating Patient Perspective on Communication of MTB findings
Elizabeth Waller, Patient Representative, Spain
Cristina Nogueira, Patient Representative, Portugal
Siri Strand, Oslo University Hospital Comprehensive Cancer Centre, Norway
Matteo Pallocca, CNR IEOMI and BBMRI.it, Italy
Jörg Haier, Comprehensive Cancer Centre Mecklenburg-Vorpommern, Germany
Luigi de Petris, Karolinska Comprehensive Cancer Center and Karolinska Institutet, Sweden
11:45 – 12:45 Session 5: Future Directions in Precision Oncologyy
11:45 – 11:55 Proteogenomics: Connecting Cancer Genotype with Molecular Phenotype for Improved Treatment Prediction
Janne Lehtiö, Karolinska Institutet, SciLifeLab and Karolinska University Hospital, Sweden
11:55 – 12:05 Precision Targeting of the Tumour Microenvironment
Kristian Pietras, Lund University Cancer Centre and SciLifeLab, Sweden
12:05 – 12:15 The Role of Imaging Biomarkers in Precision Oncology
Faisal Mahmood, Odense University Hospital and University of Southern Denmark,Denmark
12:15 – 12:25 Patient-derived Tumouroids for Next Generation Molecular Tumour Boards
Åsmund Flobak, Norwegian University of Science and Technology, St Olav's University Hospital and SINTEF, Norway
12:25 – 12:45 Panel Discussion
Moderator to be confirmed
12:45 – 13:00 Closing Remarks
Gro Live Fagereng, Oslo University Hospital Comprehensive Cancer Centre, Norway
Alejandro Piris Giménez, Vall d’Hebron Institute of Oncology, Spain
13:00 - 14:00   Lunch Break